DSGN revenueQ3 2026$0
DSGN revenue was $0 in fiscal Q3 2026 (ended Sep 30, 2026), compared with $0 a year earlier. For the full fiscal 2025 it was $0, compared with $0 in fiscal 2024.
Design Therapeutics Inc. (DSGN) financials
For the twelve months ended Sep 30, 2026, Design Therapeutics Inc. reported $0 of revenue and -$74.09M of net income.
- Revenue, TTM
- $0
- Net income, TTM
- -$74.09M
- Free cash flow, TTM
- -$59.37M
- EPS, diluted, TTM
- -$1.20
- Cash
- $15.25M
- Market cap
- $653.8M
FY2020FY2025
FY2020FY2025
FY2020FY2025
DSGN revenue and earnings growth
DSGN net incomeQ3 2026-$20.29M
DSGN net income was -$20.29M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$17.00M a year earlier. For the full fiscal 2025 it was -$69.79M, compared with -$49.59M in fiscal 2024.
DSGN EPSQ3 2026-$0.32
DSGN diluted EPS was -$0.32 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.30 a year earlier. For the full fiscal 2025 it was -$1.22, compared with -$0.88 in fiscal 2024.
DSGN free cash flowQ3 2026-$15.39M
DSGN free cash flow was -$15.39M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$11.16M a year earlier. For the full fiscal 2025 it was -$54.55M, compared with -$43.45M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | - | - | - | $226.0K |
| Research and development | $59.13M | $44.35M | $57.06M | $48.61M | $24.78M | $6.06M |
| Selling, general and admin | $20.34M | $18.03M | $21.13M | $18.98M | $11.05M | $2.50M |
| Operating income | -$79.47M | -$62.38M | -$78.19M | -$67.59M | -$35.83M | -$8.33M |
| Income tax | $0 | $0 | - | - | - | - |
| Net income | -$69.79M | -$49.59M | -$66.86M | -$63.31M | -$35.53M | -$8.28M |
| EPS, basic | -$1.22 | -$0.88 | -$1.19 | -$1.14 | -$0.77 | -$0.52 |
| EPS, diluted | -$1.22 | -$0.88 | -$1.19 | -$1.14 | -$0.77 | -$0.52 |
| Diluted shares | 57.3M | 56.6M | 56.0M | 55.7M | 45.9M | 15.8M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $16.86M | $22.56M | $21.20M | $26.50M | $298.57M | $2.38M |
| Short-term investments | $202.99M | $222.91M | $260.60M | $303.89M | $85.50M | $33.71M |
| Current assets | $223.78M | $248.04M | $284.58M | $335.12M | $385.44M | $36.23M |
| Total assets | $226.20M | $252.09M | $289.64M | $341.14M | $390.56M | $36.52M |
| Current liabilities | $13.05M | $8.46M | $9.62M | $10.78M | $5.28M | $2.33M |
| Total liabilities | $13.70M | $10.00M | $11.96M | $13.83M | $8.43M | $2.48M |
| Shareholders' equity | $212.50M | $242.10M | $277.69M | $327.31M | $382.13M | -$11.31M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$54.36M | -$43.10M | -$58.56M | -$51.32M | -$29.38M | -$8.67M |
| Capital expenditures | $193.0K | $340.0K | $256.0K | $918.0K | $1.54M | $76.0K |
| Free cash flow | -$54.55M | -$43.45M | -$58.82M | -$52.23M | -$30.91M | -$8.74M |
| Investing cash flow | $22.91M | $43.95M | $52.54M | -$220.99M | -$53.64M | -$33.56M |
| Financing cash flow | $25.74M | $513.0K | $724.0K | $235.0K | $379.21M | $44.53M |
| Stock-based compensation | $14.55M | $13.07M | $13.09M | $10.93M | $4.69M | $450.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating margin | - | - | - | - | - | -3685.8% |
| Net margin | - | - | - | - | - | -3663.7% |
| Free cash flow margin | - | - | - | - | - | -3869.5% |
| Return on equity | -32.8% | -20.5% | -24.1% | -19.3% | -9.3% | - |
| Return on assets | -30.9% | -19.7% | -23.1% | -18.6% | -9.1% | -22.7% |
| Current ratio | 17.14 | 29.31 | 29.58 | 31.10 | 72.96 | 15.55 |
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | - | - | - | - | - |
| Research and development | $16.93M | $16.39M | $14.38M | $13.43M | $14.59M | $15.74M | $15.38M | $12.16M | $11.88M | $10.52M | $9.80M | $11.01M |
| Selling, general and admin | $5.30M | $5.79M | $5.33M | $4.74M | $4.72M | $5.83M | $5.04M | $4.54M | $4.37M | $4.53M | $4.60M | $4.11M |
| Operating income | -$22.23M | -$22.18M | -$19.71M | -$18.17M | -$19.31M | -$21.57M | -$20.42M | -$16.69M | -$16.25M | -$15.04M | -$14.40M | -$15.12M |
| Net income | -$20.29M | -$20.16M | -$17.64M | -$16.00M | -$17.00M | -$19.08M | -$17.71M | -$13.65M | -$13.04M | -$11.79M | -$11.11M | -$11.84M |
| EPS, basic | -$0.32 | -$0.32 | -$0.29 | -$0.27 | -$0.30 | -$0.34 | -$0.31 | -$0.24 | -$0.23 | -$0.21 | -$0.20 | -$0.20 |
| EPS, diluted | -$0.32 | -$0.32 | -$0.29 | -$0.27 | -$0.30 | -$0.34 | -$0.31 | -$0.24 | -$0.23 | -$0.21 | -$0.20 | -$0.20 |
| Diluted shares | 63.0M | 62.5M | 61.4M | - | 57.0M | 56.9M | 56.8M | - | 56.6M | 56.6M | 56.5M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $15.25M | $12.91M | $12.77M | $16.86M | $15.09M | $19.70M | $13.67M | $22.56M | $30.33M | $45.70M | $29.40M | $21.20M |
| Short-term investments | $193.36M | $194.49M | $210.05M | $202.99M | $190.88M | $196.57M | $216.01M | $222.91M | $223.75M | $215.32M | $241.29M | $260.60M |
| Current assets | $213.96M | $212.01M | $227.05M | $223.78M | $209.03M | $219.79M | $233.64M | $248.04M | $257.24M | $264.84M | $273.89M | $284.58M |
| Total assets | $216.81M | $215.13M | $230.44M | $226.20M | $211.77M | $222.89M | $237.47M | $252.09M | $261.63M | $269.58M | $278.79M | $289.64M |
| Current liabilities | $12.75M | $11.24M | $10.19M | $13.05M | $11.17M | $8.75M | $8.24M | $8.46M | $7.43M | $6.39M | $7.09M | $9.62M |
| Total liabilities | $14.61M | $13.27M | $12.39M | $13.70M | $12.05M | $9.85M | $9.56M | $10.00M | $9.18M | $8.34M | $9.24M | $11.96M |
| Shareholders' equity | $202.20M | $201.86M | $218.05M | $212.50M | $199.72M | $213.04M | $227.92M | $242.10M | $252.45M | $261.24M | $269.56M | $277.69M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.38M | -$15.52M | -$16.43M | -$11.97M | -$11.16M | -$14.44M | -$16.79M | -$9.86M | -$9.55M | -$11.26M | -$12.44M | -$12.80M |
| Capital expenditures | $15.0K | $21.0K | $0 | $34.0K | $0 | $87.0K | $72.0K | $0 | -$16.0K | $161.0K | $195.0K | $27.0K |
| Free cash flow | -$15.39M | -$15.54M | -$16.43M | -$12.00M | -$11.16M | -$14.53M | -$16.86M | -$9.86M | -$9.56M | -$11.42M | -$12.63M | -$12.82M |
| Investing cash flow | $189.0K | $15.06M | -$7.59M | -$11.58M | $6.51M | $20.12M | $7.87M | $1.83M | -$5.83M | $27.33M | $20.62M | $5.55M |
| Financing cash flow | $17.53M | $605.0K | $19.93M | $25.32M | $37.0K | $361.0K | $23.0K | $263.0K | $1.0K | $229.0K | $20.0K | $501.0K |
| Stock-based compensation | $4.05M | $3.87M | $3.92M | $3.44M | $3.59M | $3.98M | $3.54M | $3.47M | $3.12M | $3.30M | $3.18M | $2.72M |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 16.78 | 18.86 | 22.28 | 17.14 | 18.71 | 25.13 | 28.37 | 29.31 | 34.61 | 41.42 | 38.61 | 29.58 |
Source: XBRL data Design Therapeutics Inc. files with the SEC, latest filing dated Nov 4, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
DSGN peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| DSGN | $0 | - | -$74.09M | - | $653.8M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
DSGN FAQ
7 questionsWhat is DSGN revenue?
Design Therapeutics Inc. (DSGN) reported $0 of revenue for the twelve months ended Sep 30, 2026. Revenue for fiscal 2025 was $0.Is DSGN profitable?
No. Design Therapeutics Inc. reported a net loss of $74.09M for the twelve months ended Sep 30, 2026.How much cash and debt does DSGN have?
Design Therapeutics Inc. reported $15.25M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is DSGN free cash flow?
Design Therapeutics Inc. generated -$59.37M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$59.30M less capital expenditures.What is DSGN earnings per share?
Diluted earnings per share were -$1.20 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did DSGN last report financial results?
The latest statements here come from Design Therapeutics Inc.'s 10-Q filed on Nov 4, 2026, covering the period ended Sep 30, 2026.Where does this DSGN financial data come from?
Quantisnow builds these statements from the structured XBRL data Design Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.